INT34692

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1988
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 3.86
Pain Relevance 1.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

ras (Mus musculus)
Pain Link Frequency Relevance Heat
Paracetamol 12 95.36 Very High Very High Very High
Analgesic 1 78.08 Quite High
Pain 1 77.72 Quite High
Versed 2 74.80 Quite High
cva 1 67.96 Quite High
headache 1 65.92 Quite High
Inflammatory response 1 63.52 Quite High
cINOD 6 58.24 Quite High
cytokine 1 55.84 Quite High
anesthesia 2 25.00 Low Low
Disease Link Frequency Relevance Heat
Watson Syndrome 19 99.30 Very High Very High Very High
Toxicity 10 96.72 Very High Very High Very High
Cancer 17 95.24 Very High Very High Very High
Erythrocytosis 9 93.00 High High
Disease 1 92.36 High High
Stress 3 91.68 High High
Recurrence 2 81.52 Quite High
Liver Failure 1 80.92 Quite High
Malignant Neoplastic Disease 6 79.68 Quite High
Pain 1 77.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The functional role of Ras activation was studied by a single intraperitoneal injection of the neutral sphingomyelinase and farnesyltransferase inhibitor (FTI) manumycin A (1 mg/kg), which lowers induction of Ras-GTP and serum amounts of alanine aminotransferase (ALT).
Negative_regulation (lowers) of Positive_regulation (induction) of Ras
1) Confidence 0.45 Published 2009 Journal Hepatology Section Abstract Doc Link 19739265 Disease Relevance 0.64 Pain Relevance 0.72
One proposed function of the NF1 gene product neurofibromin is the downregulation of activated RAS, based on the conversion of RAS-GTP to RAS-GDP via its GTPase enzymatic activity [6].
Negative_regulation (downregulation) of Positive_regulation (activated) of RAS associated with watson syndrome
2) Confidence 0.06 Published 2004 Journal Cancer Cell Int Section Body Doc Link PMC425591 Disease Relevance 1.81 Pain Relevance 0.19
A reduction in systemic perfusion pressure and an elevation in renal vascular resistance, via activation of the RAS are likely to be responsible for i.p. urethane-induced reductions in renal clearance.
Negative_regulation (reductions) of Positive_regulation (activation) of RAS
3) Confidence 0.04 Published 1988 Journal Arch Int Pharmacodyn Ther Section Abstract Doc Link 3069064 Disease Relevance 0.32 Pain Relevance 0.04
A reduction in systemic perfusion pressure and an elevation in renal vascular resistance, via activation of the RAS are likely to be responsible for i.p. urethane-induced reductions in renal clearance.
Negative_regulation (reduction) of Positive_regulation (activation) of RAS
4) Confidence 0.04 Published 1988 Journal Arch Int Pharmacodyn Ther Section Abstract Doc Link 3069064 Disease Relevance 0.33 Pain Relevance 0.04
Inactivation of the renin-angiotensin system (RAS) by an angiotensin-converting enzyme (ACE) inhibitor, or an angiotensin II type 1 AT1 receptor blocker represents the most effective, safe, and well-tolerated therapeutic modality.
Negative_regulation (represents) of Positive_regulation (Inactivation) of RAS
5) Confidence 0.01 Published 2003 Journal Kidney Int. Section Abstract Doc Link 12631334 Disease Relevance 0.77 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox